Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Other Working Capital Changes (2016 - 2025)

Fennec Pharmaceuticals' Other Working Capital Changes history spans 15 years, with the latest figure at $1.4 million for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes rose 296.8% year-over-year to $1.4 million, compared with a TTM value of $1.3 million through Dec 2025, up 259.17%, and an annual FY2025 reading of $1.3 million, up 259.17% over the prior year.
  • Other Working Capital Changes for Q4 2025 was $1.4 million at Fennec Pharmaceuticals, up from -$520000.0 in the prior quarter.
  • The five-year high for Other Working Capital Changes was $25.1 million in Q2 2024, with the low at -$25.4 million in Q3 2024.
  • Average Other Working Capital Changes over 5 years is $86000.0, with a median of -$2000.0 recorded in 2025.
  • Biggest YoY gain for Other Working Capital Changes was 13898.35% in 2024; the steepest drop was 11973.81% in 2024.
  • Tracing FENC's Other Working Capital Changes over 5 years: stood at $823000.0 in 2021, then crashed by 40.22% to $492000.0 in 2022, then increased by 5.69% to $520000.0 in 2023, then tumbled by 232.12% to -$687000.0 in 2024, then surged by 296.8% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Other Working Capital Changes are $1.4 million (Q4 2025), -$520000.0 (Q3 2025), and $437000.0 (Q2 2025).